What is the share price of Concord Biotech Ltd (CONCORDBIO) today?
The share price of CONCORDBIO as on 5th December 2025 is ₹1418.70. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Concord Biotech Ltd (CONCORDBIO) share?
The past returns of Concord Biotech Ltd (CONCORDBIO) share are- Past 1 week: -2.63%
- Past 1 month: -4.05%
- Past 3 months: -16.01%
- Past 6 months: -25.29%
- Past 1 year: -35.74%
- Past 3 years: N/A%
- Past 5 years: 48.66%
What are the peers or stocks similar to Concord Biotech Ltd (CONCORDBIO)?
The peers or stocks similar to Concord Biotech Ltd (CONCORDBIO) include:What is the dividend yield % of Concord Biotech Ltd (CONCORDBIO) share?
The current dividend yield of Concord Biotech Ltd (CONCORDBIO) is 0.76.What is the market cap of Concord Biotech Ltd (CONCORDBIO) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Concord Biotech Ltd (CONCORDBIO) is ₹14663.01 Cr as of 5th December 2025.What is the 52 week high and low of Concord Biotech Ltd (CONCORDBIO) share?
The 52-week high of Concord Biotech Ltd (CONCORDBIO) is ₹2451.70 and the 52-week low is ₹1345.What is the PE and PB ratio of Concord Biotech Ltd (CONCORDBIO) stock?
The P/E (price-to-earnings) ratio of Concord Biotech Ltd (CONCORDBIO) is 39.45. The P/B (price-to-book) ratio is 8.09.Which sector does Concord Biotech Ltd (CONCORDBIO) belong to?
Concord Biotech Ltd (CONCORDBIO) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Concord Biotech Ltd (CONCORDBIO) shares?
You can directly buy Concord Biotech Ltd (CONCORDBIO) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Concord Biotech Ltd
CONCORDBIO Share Price
1,418.701.22% (+17.10)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
CONCORDBIO Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
CONCORDBIO Performance & Key Metrics
CONCORDBIO Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 45.27 | 8.09 | 0.76% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.94 | 5.83 | 0.58% |
67%
Analysts have suggested that investors can buy this stock
from 6 analysts
Price Upside
Earnings Growth
Rev. Growth
CONCORDBIO Company Profile
Concord Biotech Limited, a biopharma company, engages in R&D, manufacturing, and marketing of pharmaceutical products in diverse therapeutic segments.
SUNPHARMA
PE Ratio
39.92
39.92
1Y Return
1.01%
1.01%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.21
67.21
1Y Return
13.21%
13.21%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.34%
1.34%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.81
18.81
1Y Return
5.10%
5.10%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.12
29.12
1Y Return
0.46%
0.46%
Buy Reco %
72.22
72.22
CONCORDBIO Sentiment Analysis
CONCORDBIO Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
CONCORDBIO Stock Summary · November 2025
In Q2 FY26, Concord Biotech Limited reported a revenue of Rs. 247 crores, reflecting a 21% quarter-over-quarter growth but a 20% year-over-year decline, primarily due to regulatory delays and shifts in customer procurement patterns. Despite these challenges, management remains optimistic about a recovery in the second half of the fiscal year, bolstered by strong demand for fermentation-based API products and significant regulatory advancements, including USFDA approvals. The company is strategically focusing on the Indian market and expanding its product portfolio, particularly in CAR-T cell therapies, while maintaining stable pricing for existing customers. Overall, the outlook remains positive, with expectations for improved performance and market share capture as operational efficiencies are realized.
CONCORDBIO Stock Growth Drivers
CONCORDBIO Stock Growth Drivers
6Regulatory Approvals and Market Expansion
The company has achieved significant regulatory milestones, including USFDA approval for Teriflunomide Tablets and multiple
Operational Performance and Financial Stability
The company has maintained a solid EBITDA margin of 41%, supported by expected higher revenues
CONCORDBIO Stock Challenges
CONCORDBIO Stock Challenges
6Subdued Revenue Performance
Concord Biotech Limited reported revenues of Rs. 247 crores for Q2FY26, reflecting a year-on-year decline
Regulatory Delays and Compliance Issues
The company faced significant delays in the renewal application for Written Confirmation from the Central
CONCORDBIO Forecast
CONCORDBIO Forecasts
Price
Revenue
Earnings
CONCORDBIO Share Price Forecast
CONCORDBIO Share Price Forecast
2025
Current
₹1,401.60
Baseline
Forecast for Dec 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹1,401.60
Baseline
Forecast for Dec 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
CONCORDBIO Company Revenue Forecast
CONCORDBIO Company Revenue Forecast
2025
Current
₹1.24
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹1.24
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
CONCORDBIO Stock EPS (Earnings Per Share) Forecast
CONCORDBIO Stock EPS (Earnings Per Share) Forecast
2025
Current
₹35.53
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹35.53
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
CONCORDBIO
CONCORDBIO
Income
Balance Sheet
Cash Flow
Annual Normal View
CONCORDBIO Income Statement
CONCORDBIO Income Statement
Annual Normal View
| Financial Year | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 543.85 | 630.50 | 736.35 | 890.44 | 1,054.09 | 1,244.54 | 1,181.91 | |||||||
Raw Materials | 134.79 | 150.61 | 187.99 | 195.84 | 241.28 | 320.30 | 688.44 | |||||||
| Power & Fuel Cost | 37.30 | 39.86 | 71.64 | 97.65 | 104.97 | 112.23 | ||||||||
| Employee Cost | 62.24 | 64.25 | 95.69 | 110.28 | 123.05 | 138.93 | ||||||||
| Selling & Administrative Expenses | 31.74 | 31.21 | 67.90 | 82.93 | 91.08 | 99.31 | ||||||||
| Operating & Other expenses | 41.73 | 2.98 | 19.42 | 22.51 | 24.37 | 23.79 | ||||||||
EBITDA | 236.05 | 341.59 | 293.71 | 381.23 | 469.34 | 549.98 | 493.47 | |||||||
| Depreciation/Amortization | 21.25 | 27.52 | 50.05 | 54.03 | 53.59 | 54.37 | 64.05 | |||||||
| PBIT | 214.80 | 314.07 | 243.66 | 327.20 | 415.75 | 495.61 | 429.42 | |||||||
| Interest & Other Items | 1.17 | 0.90 | 6.13 | 5.18 | 3.18 | 1.04 | 0.32 | |||||||
| PBT | 213.63 | 313.17 | 237.53 | 322.02 | 412.57 | 494.57 | 429.10 | |||||||
| Taxes & Other Items | 44.53 | 77.83 | 62.59 | 81.93 | 104.46 | 122.91 | 105.18 | |||||||
| Net Income | 169.10 | 235.34 | 174.94 | 240.09 | 308.11 | 371.66 | 323.92 | |||||||
| EPS | 16.16 | 22.50 | 16.72 | 22.95 | 29.45 | 35.53 | 30.96 | |||||||
| DPS | 3.57 | 0.00 | 0.47 | 6.83 | 8.75 | 10.70 | 10.70 | |||||||
| Payout ratio | 0.22 | 0.00 | 0.03 | 0.30 | 0.30 | 0.30 | 0.35 |
CONCORDBIO Company Updates
FY 2026FY 2026
Investor Presentation
Nov 13PDF
Aug 10PDF
CONCORDBIO Stock Peers
CONCORDBIO Past Performance & Peer Comparison
CONCORDBIO Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Concord Biotech Ltd | 39.45 | 8.09 | 0.76% |
| Sun Pharmaceutical Industries Ltd | 39.92 | 6.02 | 0.88% |
| Torrent Pharmaceuticals Ltd | 67.21 | 16.92 | 0.84% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
CONCORDBIO Stock Price Comparison
Compare CONCORDBIO with any stock or ETFCompare CONCORDBIO with any stock or ETF
CONCORDBIO
CONCORDBIO Holdings
CONCORDBIO Shareholdings
CONCORDBIO Promoter Holdings Trend
CONCORDBIO Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
CONCORDBIO Institutional Holdings Trend
CONCORDBIO Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Decreased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has decreased by 1.07%
CONCORDBIO Shareholding Pattern
CONCORDBIO Shareholding Pattern
CONCORDBIO Shareholding History
CONCORDBIO Shareholding History
Foreign Institutions
Mutual Funds Invested in CONCORDBIO
Mutual Funds Invested in CONCORDBIO
No mutual funds holding trends are available
Top 5 Mutual Funds holding Concord Biotech Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.8388% | Percentage of the fund’s portfolio invested in the stock 0.75% | Change in the portfolio weight of the stock over the last 3 months -0.17% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 83/115 (-4) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.7385% | Percentage of the fund’s portfolio invested in the stock 0.64% | Change in the portfolio weight of the stock over the last 3 months 0.64% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 58/85 (+23) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.7072% | Percentage of the fund’s portfolio invested in the stock 2.55% | Change in the portfolio weight of the stock over the last 3 months -0.30% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 22/34 (-5) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing CONCORDBIO stock
smallcases containing CONCORDBIO stock
Looks like this stock is not in any smallcase yet.
CONCORDBIO Events
CONCORDBIO Events
CONCORDBIO Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
CONCORDBIO Dividend Trend
No dividend trend available
CONCORDBIO Upcoming Dividends
CONCORDBIO Upcoming Dividends
No upcoming dividends are available
CONCORDBIO Past Dividends
CONCORDBIO Past Dividends
Cash Dividend
Ex DateEx DateSep 3, 2025
Final
Final | Div/Share: ₹10.70
Dividend/Share
₹10.70
Ex DateEx Date
Sep 3, 2025
Cash Dividend
Ex DateEx DateJun 21, 2024
Final
Final | Div/Share: ₹8.75
Dividend/Share
₹8.75
Ex DateEx Date
Jun 21, 2024
CONCORDBIO Stock News & Opinions
CONCORDBIO Stock News & Opinions
Articles & Videos
Earnings
Concord Biotech consolidated net profit declines 33.59% in the September 2025 quarter
Net profit of Concord Biotech declined 33.59% to Rs 63.58 crore in the quarter ended September 2025 as against Rs 95.74 crore during the previous quarter ended September 2024. Sales declined 20.35% to Rs 247.06 crore in the quarter ended September 2025 as against Rs 310.18 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales247.06310.18 -20 OPM %35.8243.11 - PBDT104.08143.65 -28 PBT85.68130.34 -34 NP63.5895.74 -34 Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Earnings
Concord Biotech standalone net profit declines 36.27% in the September 2025 quarter
Net profit of Concord Biotech declined 36.27% to Rs 62.90 crore in the quarter ended September 2025 as against Rs 98.70 crore during the previous quarter ended September 2024. Sales declined 20.35% to Rs 247.06 crore in the quarter ended September 2025 as against Rs 310.18 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales247.06310.18 -20 OPM %36.6544.06 - PBDT103.92146.60 -29 PBT85.53133.29 -36 NP62.9098.70 -36 Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Concord Biotech announces board meeting date
Concord Biotech will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Spotlight
Concord Biotech gains after successful EU-GMP inspection at Limbassi facility
The inspection was conducted by EU-GMP authorities from 18 August to 21 August 2025. The company stated that this milestone marks a significant achievement, as the successful outcome not only validates its commitment to global quality standards but also opens avenues to expand its presence in international markets. The EU-GMP approval will allow Concord to explore commercial opportunities across multiple EU territories and other regulated geographies, strengthening its global footprint and supporting its growth strategy. Concord added that the inspection outcome reaffirms its commitment to the highest standards of quality, safety, and regulatory compliance, highlighting its focus on operational excellence and alignment with international regulatory expectations. Concord Biotech is involved in manufacturing fermentation and semi-synthetic biopharmaceutical APIs with immunosuppressants as its key therapeutic segment. The company's consolidated net profit fell 26.1% to Rs 44.06 crore on a 5.5% decline in revenue from operations to Rs 203.99 crore in Q1 FY26 over Q1 FY25. Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Concord Biotech's API unit in Limbassi concludes EU-GMP inspection
Concord Biotech announced that the European Union Good Manufacturing Practice (EU-GMP) authorities have conducted their first inspection of its Active Pharmaceutical Ingredients (API) manufacturing facility located at Limbassi. The inspection was carried out from 18 August 2025 to 21 August 2025. This milestone marks a significant achievement for Concord, as a successful EU-GMP inspection not only validates our commitment to global quality standards but also paves the way for expanding our footprint into new international markets. The approval will enable Concord to explore commercial opportunities across various EU territories and other regulated geographies, strengthening our global presence and growth trajectory, said the company. Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Concord Biotech to conduct AGM
Concord Biotech announced that the Annual General Meeting(AGM) of the company will be held on 9 September 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Concord Biotech fixes record date for dividend
Concord Biotech has fixed 03 September 2025 as record date for the purpose of identifying the members entitlement to receive dividend of Rs. 10.70 per equity share having face value of Re. 1/- each fully paid-up for the financial year 2024- 25.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Concord Biotech consolidated net profit declines 26.06% in the June 2025 quarter
Net profit of Concord Biotech declined 26.06% to Rs 44.06 crore in the quarter ended June 2025 as against Rs 59.59 crore during the previous quarter ended June 2024. Sales declined 5.47% to Rs 203.99 crore in the quarter ended June 2025 as against Rs 215.80 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales203.99215.80 -5 OPM %30.1037.66 - PBDT76.5192.70 -17 PBT58.7379.52 -26 NP44.0659.59 -26 Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Concord Biotech standalone net profit declines 26.91% in the June 2025 quarter
Net profit of Concord Biotech declined 26.91% to Rs 42.57 crore in the quarter ended June 2025 as against Rs 58.24 crore during the previous quarter ended June 2024. Sales declined 5.47% to Rs 203.99 crore in the quarter ended June 2025 as against Rs 215.80 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales203.99215.80 -5 OPM %30.1037.66 - PBDT75.0391.34 -18 PBT57.2578.16 -27 NP42.5758.24 -27 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Concord Biotech to declare Quarterly Results
Concord Biotech will hold a meeting of the Board of Directors of the Company on 8 August 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 18.01%, vs industry avg of 10.03%
Over the last 5 years, market share increased from 0.22% to 0.3%
Over the last 5 years, net income has grown at a yearly rate of 17.06%, vs industry avg of 20.02%